Haleon plc (LON:HLN)
323.20
+3.80 (1.19%)
Nov 2, 2026, 5:05 PM GMT
Haleon Revenue
Haleon had revenue of 5.60B GBP in the half year ending June 30, 2026, a decrease of -1.62%. This brings the company's total for the last twelve months to 11.15B, up 1.21% year-over-year. In the year 2025, Haleon had annual revenue of 11.03B, down -1.81%. That makes Haleon the 1,051st largest company in the world by revenue and 42nd in the United Kingdom.
Revenue (ttm)
11.15B
Revenue Growth
+1.21%
P/S Ratio
2.55
Revenue / Employee
454.53K
Employees
24,535
Market Cap
28.47B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Haleon breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.03B | -203.00M | -1.81% |
| Dec 31, 2024 | 11.23B | -69.00M | -0.61% |
| Dec 31, 2023 | 11.30B | 444.00M | 4.09% |
| Dec 31, 2022 | 10.86B | 1.31B | 13.76% |
| Dec 31, 2021 | 9.55B | -347.00M | -3.51% |
| Dec 31, 2020 | 9.89B | 1.41B | 16.65% |
| Dec 31, 2019 | 8.48B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hikma Pharmaceuticals | 2.58B |
| HUTCHMED (China) | 413.87M |
| ECO Animal Health Group | 87.53M |
| Allergy Therapeutics | 57.29M |
| Shield Therapeutics | 44.19M |
| Provexis | 1.26M |
| Chill Brands Group | 955.18K |
Haleon News
- 14 hours ago - Haleon downgraded to Hold from Buy at Berenberg - TheFly
- 15 hours ago - Haleon removed from European Conviction List at Goldman Sachs - TheFly
- 3 days ago - Haleon price target lowered to 290 GBp from 295 GBp at JPMorgan - TheFly
- 3 days ago - Haleon price target lowered to 390 GBp from 455 GBp at Citi - TheFly
- 3 days ago - Haleon price target lowered to 310 GBp from 390 GBp at RBC Capital - TheFly
- 4 days ago - Haleon upgraded to Hold from Sell at Deutsche Bank - TheFly
- 4 days ago - Shares in consumer healthcare firm Haleon sink amid weak demand for cold and flu medicine - This is Money
- 4 days ago - Haleon plc Announces Commencement of £500m Share Buyback Programme - Nasdaq